Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NYSE:EBS NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$6.76-0.8%$7.90$6.00▼$11.31$1.42B1.053.88 million shs6.64 million shsCLDXCelldex Therapeutics$26.40-3.4%$24.33$14.40▼$29.93$1.74B1.331.03 million shs459,593 shsEBSEmergent Biosolutions$9.53-0.7%$8.65$4.02▼$12.73$508.59M2.041.19 million shs355,264 shsJNJJohnson & Johnson$192.00+0.4%$179.68$140.68▼$194.40$462.51B0.48.92 million shs5.06 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+6.07%-6.46%-11.56%-21.72%-8.96%CLDXCelldex Therapeutics+3.29%+0.37%+11.59%+19.02%-7.01%EBSEmergent Biosolutions+5.58%-2.69%+20.60%+32.11%+4.72%JNJJohnson & Johnson+0.04%+0.64%+7.59%+17.13%+16.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$6.76-0.8%$7.90$6.00▼$11.31$1.42B1.053.88 million shs6.64 million shsCLDXCelldex Therapeutics$26.40-3.4%$24.33$14.40▼$29.93$1.74B1.331.03 million shs459,593 shsEBSEmergent Biosolutions$9.53-0.7%$8.65$4.02▼$12.73$508.59M2.041.19 million shs355,264 shsJNJJohnson & Johnson$192.00+0.4%$179.68$140.68▼$194.40$462.51B0.48.92 million shs5.06 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals+6.07%-6.46%-11.56%-21.72%-8.96%CLDXCelldex Therapeutics+3.29%+0.37%+11.59%+19.02%-7.01%EBSEmergent Biosolutions+5.58%-2.69%+20.60%+32.11%+4.72%JNJJohnson & Johnson+0.04%+0.64%+7.59%+17.13%+16.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.77Moderate Buy$19.18183.75% UpsideCLDXCelldex Therapeutics 2.50Moderate Buy$43.7861.57% UpsideEBSEmergent Biosolutions 2.33Hold$13.5038.83% UpsideJNJJohnson & Johnson 2.73Moderate Buy$199.593.92% UpsideCurrent Analyst Ratings BreakdownLatest EBS, JNJ, CLDX, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025JNJJohnson & JohnsonArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$210.0010/15/2025JNJJohnson & JohnsonRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$174.00 ➝ $209.0010/15/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$190.0010/15/2025JNJJohnson & JohnsonStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$165.00 ➝ $190.0010/15/2025BCRXBioCryst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$24.00 ➝ $26.0010/15/2025BCRXBioCryst PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.0010/15/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.0010/15/2025BCRXBioCryst PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$17.00 ➝ $27.0010/15/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$213.00 ➝ $215.0010/15/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$198.00 ➝ $204.0010/14/2025JNJJohnson & JohnsonCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.15N/AN/A($2.30) per share-2.94CLDXCelldex Therapeutics$7.02M256.33N/AN/A$11.26 per share2.41EBSEmergent Biosolutions$1.04B0.50$2.06 per share4.73$8.91 per share1.09JNJJohnson & Johnson$88.82B5.21$13.20 per share14.55$29.69 per share6.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.28-6.41%N/A-1.78%11/3/2025 (Estimated)CLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)EBSEmergent Biosolutions-$190.60M$2.453.974.70N/A16.38%24.63%8.97%10/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$9.3518.5417.352.4027.26%33.08%13.30%N/ALatest EBS, JNJ, CLDX, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025CLDXCelldex Therapeutics-$0.88N/AN/AN/A$1.12 millionN/A11/3/2025Q3 2025BCRXBioCryst Pharmaceuticals$0.05N/AN/AN/A$162.91 millionN/A10/29/2025Q3 2025EBSEmergent Biosolutions-$0.01N/AN/AN/A$203.67 millionN/A10/14/2025Q3 2025JNJJohnson & Johnson$2.76$2.80+$0.04$2.12$23.73 billion$23.99 billion8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 million7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.71%N/A55.61%64 YearsLatest EBS, JNJ, CLDX, and BCRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date10/14/2025JNJJohnson & Johnsonquarterly$1.302.72%11/25/202511/25/202512/9/20257/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22CLDXCelldex TherapeuticsN/A19.6719.67EBSEmergent Biosolutions1.255.663.00JNJJohnson & Johnson0.501.010.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AEBSEmergent Biosolutions78.40%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics4.40%EBSEmergent Biosolutions1.20%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableEBSEmergent Biosolutions2,42053.35 million52.71 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableEBS, JNJ, BCRX, and CLDX HeadlinesRecent News About These CompaniesJohnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy1 hour ago | benzinga.comJ&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan1 hour ago | zacks.comJohnson & Johnson: Earnings Beat, High Technical Momentum, UK Talc Suits Loom 3 hours ago | talkmarkets.comJamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase3 hours ago | fool.comJohnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims4 hours ago | benzinga.comRaymond James Maintains Johnson & Johnson (JNJ) Outperform Recommendation4 hours ago | msn.comJohnson & Johnson Sued in U.K. Over Baby Powder Cancer Claims5 hours ago | nytimes.comETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook5 hours ago | zacks.comJohnson & Johnson Stock (JNJ) Flattens as it Faces U.K. Talcum Powder Cancer Claims5 hours ago | tipranks.comJohnson & Johnson succeeds in late-stage multiple myeloma trial5 hours ago | seekingalpha.comJohnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks5 hours ago | benzinga.comExclusive: Ulta Beauty’s new CFO is a Johnson & Johnson veteran tasked to help lead the company’s next chapter5 hours ago | fortune.comLeerink Partnrs Brokers Increase Earnings Estimates for JNJOctober 16 at 8:08 AM | marketbeat.comTECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of careOctober 16 at 8:00 AM | prnewswire.comRevolve Wealth Partners LLC Has $1.05 Million Stock Position in Johnson & Johnson $JNJOctober 16 at 4:39 AM | marketbeat.com1,360 Shares in Johnson & Johnson $JNJ Bought by Jag Capital Management LLCOctober 16 at 4:39 AM | marketbeat.comAlpine Woods Capital Investors LLC Decreases Stock Position in Johnson & Johnson $JNJOctober 16 at 4:39 AM | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Cornerstone Wealth Group LLCOctober 16 at 4:39 AM | marketbeat.comVerdence Capital Advisors LLC Cuts Holdings in Johnson & Johnson $JNJOctober 16 at 4:28 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Atria Wealth Solutions Inc.October 16 at 4:28 AM | marketbeat.comJohnson & Johnson $JNJ Stock Position Reduced by Envestnet Portfolio Solutions Inc.October 16 at 4:27 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Dividend Stocks to Hold Through Market Volatility This FallBy Chris Markoch | September 16, 20253 Small-Cap Stocks to Watch After the Fed’s Rate CutsBy Chris Markoch | September 24, 2025Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma GiantsBy Gabriel Osorio-Mazilli | October 6, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025Johnson & Johnson Stock Can Keep Rising as Strategy Pays OffBy Thomas Hughes | October 15, 2025EBS, JNJ, BCRX, and CLDX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$6.76 -0.06 (-0.81%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$26.40 -0.94 (-3.44%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Emergent Biosolutions NYSE:EBS$9.53 -0.07 (-0.70%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Johnson & Johnson NYSE:JNJ$192.00 +0.83 (+0.43%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
